500 million men suffer from erectile dysfunction and premature ejaculation worldwide. Dicot is developing a modern potency drug with the ambition of creating a therapeutic drug that has a longer lasting effect and fewer side effects than those found on the market today.
News | 2024-06-06
LIB-01 appears to affect metabolic diseases. New patent application is submitted.
New results show that LIB-01 unexpectedly appears to influence several conditions and diseases that are commonly characterized by dysfunction in the body's metabolism. These include conditions such as obesity, diabetes and high blood pressure.
Read More >News | 2024-08-13
Rights Issue August 2024
The subscription period for our rights issue is from August 16-30, which, if fully subscribed, will raise approximately SEK 123 million and is secured to approximately SEK 80 million. Visit our rights issue page for more information.
Read More >News | 2024-09-04
Unit issue subcribed to 124%!
“With this fine outcome, we can, backed by a strong financial position, take the potency drug candidate LIB-01 through the proof of concept phase, while also investing in the development of new indications”, says CEO Elin Trampe
Read More >
The global market for treating sexual dysfunctions is annually worth around 8 billion USD and will increase due to underlying causes such as growing number of elderly
Today's potency drugs were launched over twentyfive years ago and have limitations
Up to 35% of men with erection problems do not respond to current treatments. LIB-01 works differently and opens up the possibility of being helped
Existing drugs have a duration of action of maximum 36 hours. According to studies, LIB-01 can have an effect lasting at least seven days
Sexual medicine experts states that there is a great need for new potency drugs
In Sweden only one out of four seeks medical help for erectile dysfunction due to the condition's stigma
The ambition with LIB-01
- Longer duration
- Effective for everyone
- Minimal side-effects
